Sentence examples for disease substrate from inspiring English sources

This orally active iminosugar inhibits the biosynthesis of glucosylceramides, which accumulate pathologically in macrophages of patients with Gaucher disease (substrate reduction therapy, SRT).

Variance in the magnitude of the response to CRT is not fully understood but is likely due to multiple factors, including idiosyncrasy in the disease substrate.

The multilobular GA structure frequently observed in eyes with CNV of the present study may represent an underlying disease substrate, for example, the choroidal vasculature, recently reported by Xu and associates.

Specific allelic variants (single nucleotide polymorphisms, SNP), associated with risk factors for disease and substrate kinetics has been often reported to be sex specific (Halsall et al., 2000; Galluzzi et al., 2001; Talmud and Humphries, 2001).

In contrast, mildly impaired or demented individuals who have negative Aβ amyloid biomarker studies may be presumed to have non-Alzheimer's disease pathogenic substrates (Rabinovici et al., 2007).

For such cases, the development of inhibitors that are as similar as possible to the disease-related substrates has been hypothesized as an effective strategy for reducing resistance.

Recently there is also increasing interest in the role of small vessel disease as a substrate for functional decline.

Carriers for delivery of genes consisted of neutral and hydrophilic polymer as the main chain and disease-specific peptide substrate as side chains; we named polymer-peptide conjugates (PPC).

Indeed, more work is required to understand mechanisms underlying the effects of transcranial stimulation in health and disease and also substrates of inter-individual variability in order to optimize dosing and methodological designs and safety aspects.

Neurodegenerative metabolic disorders such as mucopolysaccharidosis IIIB (MPSIIIB or Sanfilippo disease) accumulate undegraded substrates in the brain and are often unresponsive to enzyme replacement treatments due to the impermeability of the blood brain barrier to enzyme.

The patients with type 1 Gaucher's disease were not receiving substrate reduction therapy.